Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
- Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
- Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
- Don’t Cause Confusion in Drug Distribution in Tax-Linked Drug Re-Pricing: JPWA
July 25, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
- Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
- Nobelpharma’s Tympanic Membrane Perforation Treatment Up for MHLW Panel Review on Aug. 1
July 23, 2019
- LDP’s Eto Secures Upper House Seat
July 22, 2019
- PMDA Reviewing Risks for Xeljanz and More
July 22, 2019
- Label Revisions Ordered for Opdivo, Keytruda, Ibrance and More
July 10, 2019
- LDP Lawmaker Seiichi Eto Launches Campaign for Upper House Election
July 5, 2019
- No Discussion in Progress for Health Coverage of Risk Reducing Mastectomies for Breast Cancer: Health Minister
July 4, 2019
- Hayashi of Japan Pension Service Tapped for Economic Affairs Division Director: MHLW Personnel Shakeup
July 3, 2019
- Biosimilar Guidelines Nearing 1st Revision in 10 Years, MHLW Taking Public Comments
July 2, 2019
- JPWA Fears October Price Revision Will “Set Back” Efforts to Improve Distribution Practices, Asks Govt for Support
July 1, 2019
- Eylea Gets Orphan Status for Neovascular Glaucoma
July 1, 2019
- MHLW Data Show Big Improvement in Single-Product, Single-Price Transaction Rates
July 1, 2019
- Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”
June 28, 2019
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…